Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals

1. A compound of the formula I

wherein:

Ring A is (C3-C8)-cycloalkanediyl or (C3-C8)-cycloalkenediyl;

R1, R2 are each independently H, F, Cl, Br, CF 3 , OCF 3 , (C1-C6)-alkyl, O—(C1-C6)-alkyl, SCF 3 , SF 5 , OCF 2 —CHF 2 , (C6-C10)-aryl, (C6-C10)-aryloxy, OH or NO 2 ; or

R1 and R2, taken together with the atoms of the phenyl ring to which they are attached, form a fused, partially saturated or unsaturated, bicyclic (C6-C10)-aryl group;

R3 is H, (C1-C6)-alkyl, (C3-C8)-cycloalkyl, (C1-C3)-alkyl-(C3-C8)-cycloalkyl, phenyl, (C1-C3)-alkyl-phenyl or (C1-C3)-alkyl which is fully or partially substituted by F;

W is CH;

o is 1;

X is (C1-C6)-alkanediyl, wherein one or more carbon atoms of said (C1-C6)-alkanediyl group are optionally replaced by oxygen atoms;

Y1 is O;

Y2 is CR12R13;

n is 0;

R4 is H, F or (C1-C6)-alkyl;

R5 is H, F or (C1-C6)-alkyl;

R6 is H or (C1-C6)-alkyl;

R7 is (C1-C6)-alkyl or O—(C1-C6)-alkyl,

wherein said (C1-C6)-alkyl and O—(C1-C6)-alkyl groups are optionally substituted by OH, NR10R11, O—(C1-C6)-alkyl, O—(C2-C6)-alkenyl, O—(C2-C6)-alkynyl, (C3-C8)-cycloalkyl, phenyl or (C5-C11)-heteroaryl,

wherein said (C3-C8)-cycloalkyl, phenyl and (C5-C11)-heteroaryl group is optionally substituted by OH, NR10R11, O—(C1-C6)-alkyl, O—(C2-C6)-alkenyl, O—(C2-C6)-alkynyl, O—(C3-C8)-cycloalkyl, O-phenyl, O—(C5-C11)-heteroaryl or (C1-C6)-alkyl,

wherein said (C1-C6)-alkyl substituent is optionally substituted by F (fully or partially) or O—(C1-C6)-alkyl,

 wherein said O—(C1-C6)-alkyl substituent is optionally substituted by F (fully or partially), Cl, Br, I, OH, NR10R11, CO—(C1-C6)-alkyl, CO—(C6-C10)-aryl, CO—(C1-C6)-alkyl-(C6-C10)-aryl, CO—(C5-C11)-heteroaryl, C(O)—O—(C1-C6)-alkyl, C(O)—O—(C1-C6)-alkyl-(C6-C10)-aryl, C(O)—O—(C6-C10)-aryl, C(O)—O—(C5-C11)-heteroaryl, SO 2 —(C1-C6)-alkyl, SO 2 —(C1-C6)-alkyl-(C6-C10)-aryl, SO 2 —(C1C6)-alkyl-SO 2 —(C1-C6)-alkyl, SO 2 —(C6-C10)-aryl, SO 2 —(C5-C11)-heteroaryl;

R8 is H or (C1-C6)-alkyl;

R9 is H or (C1-C6)-alkyl which is optionally substituted by phenyl;

R10 is H or (C1-C6)-alkyl which is optionally substituted by phenyl;

R11 is H or (C1-C6)-alkyl which is optionally substituted by phenyl;

R12 is H or (C1-C6)-alkyl;

R13 is H or (C1-C6)-alkyl;

and pharmaceutically acceptable salts thereof.

2. The compound of claim 1 wherein:

Ring A is (C 3 -C 8 )-cycloalkanediyl or (C 3 -C 8 )-cycloalkenediyl;

X is (C1-C6)-alkanediyl, wherein the C1 or C2 carbon atom (with respect to Ring A) in said (C1-C6)-alkanediyl group is optionally replaced by an oxygen atom;

and pharmaceutically acceptable salts thereof.

3. The compound of claim 2 wherein:

Ring A is cis-cyclohexane-1,3-diyl;

R1, R2 are each independently H, F, CF3, (C1-C6)-alkyl, O—(C1-C6)-alkyl or phenyl, or

R1 and R2, taken together with the atoms of the phenyl ring to which they are attached, form naphthyl;

R3 is (C1-C6)-alkyl;

W is CH;

o is 1;

X is (CH2)O or CH2—O—CH2;

Y1 is O;

Y2 is CH2;

n is 0;

R4 is H;

R5 is H;

R6 is H;

R7 is (C1-C6)-alkyl or O—(C1-C6)-alkyl,

wherein said (C1-C6)-alkyl and O—(C1-C6)-alkyl groups are optionally substituted by phenyl or (C5-C6)-heteroaryl,

wherein said phenyl and (C5-C6)-heteroaryl groups are optionally substituted by (C1-C6)-alkyl, O—(C1-C6)-alkyl or CF3;

R8 is H;

R10 is (C1-C6)-alkyl;

R11 is (C1-C6)-alkyl substituted by phenyl;

and pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of claim 1 .

5. The pharmaceutical composition of claim 4 further comprising at least one additional active ingredient.

6. The pharmaceutical composition of claim 5 wherein said additional active ingredient is an antidiabetic.

7. A method of treating disorders of insulin resistance comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 .

8. A method of treating diabetes mellitus including comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 .

9. A method of treating disorders of insulin resistance comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 in combination with at least one further active compound.